STOCK TITAN

iBio, Inc. - IBIO STOCK NEWS

Welcome to our dedicated page for iBio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on iBio stock.

iBio, Inc. (symbol: IBIO) is a specialized contract development and manufacturing organization (CDMO) that facilitates the journey from early product selection to market launch. Situated within the healthcare sector, iBio is renowned for its plant-based protein expression technologies, which are pivotal in developing vaccines, therapeutic proteins, and biopharmaceutical products.

The company operates through two primary segments: Biopharmaceuticals and Bioprocessing. iBio's Biopharmaceuticals segment focuses on the development and commercialization of product candidates aimed at addressing critical health issues such as fibrotic diseases, cancers, and infectious diseases. The Bioprocessing segment, meanwhile, involves comprehensive manufacturing and regulatory support services offered through iBio CDMO.

iBio's technology platform and state-of-the-art facilities are designed to expedite development processes, providing significant time and cost advantages over traditional approaches. The company boasts a team of skilled protein scientists, microbiologists, manufacturing experts, and regulatory professionals committed to delivering seamless scale-up from preclinical to commercial production.

Recent achievements include advancements in biotherapeutics and diagnostic products, showcasing iBio's capability to innovate and respond to global health challenges effectively. The company also maintains strategic partnerships that bolster its research and development efforts, ensuring consistent progress in the healthcare landscape.

With its focus on rapid manufacturing support and regulatory compliance, iBio stands out as a reliable partner for clients seeking efficient pathways to clinical and commercial success.

Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) reported significant growth in revenue for Q3 FY2022, totaling approximately $1.9 million, up 154% from the previous year. The company is progressing towards clinical-stage status, with plans for its COVID-19 vaccine and the IL-2-sparing anti-CD25 antibody IBIO-101. Despite an increase in R&D and G&A expenses, leading to a net loss of $12.4 million, iBio maintains adequate cash reserves of approximately $48.6 million to support operations until September 2023. A special meeting for shareholders to approve a reverse stock split is forthcoming.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
-
Rhea-AI Summary

iBio, Inc. presented preclinical data on its monoclonal antibody candidate, IBIO-101, at the Frontiers in Cancer Immunotherapy 2022 conference. The research showed that IBIO-101, utilizing iBio's FastPharming and Glycaneering technologies, matched the efficacy of a traditional anti-CD25 antibody while enhancing effector function. The company plans to advance this anti-CD25 monoclonal antibody into clinical trials next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) announced it will release its fiscal 2022 third quarter financial results on May 12, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET, providing a detailed corporate update. The company specializes in next-generation biopharmaceuticals and sustainable, plant-based manufacturing through its FastPharming System. It focuses on developing treatments for cancers, fibrotic, and infectious diseases, along with offering contract development and manufacturing services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
conferences earnings
Rhea-AI Summary

iBio (NYSE:IBIO) announced its participation in the 18th Annual Protein & Antibody Engineering Summit in Boston from May 2-5, 2022. The company will showcase research demonstrating that its FastPharming Manufacturing System produces monoclonal antibodies with a uniform G0 glycosylation pattern, unlike traditional CHO cell culture methods, which yield more heterogeneous patterns. The presentation aims to illustrate the efficacy, rapid scalability, and potential time savings in achieving in vivo proof-of-concept for therapeutic applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
-
Rhea-AI Summary

iBio (NYSEA:IBIO) announced its Chairman & CEO, Tom Isett, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. Eastern Time. This virtual presentation will be broadcasted live and archived on the iBio website under the 'News & Events' section.

iBio is known for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals, including treatments for cancers and infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Pipeline Therapeutics announced the appointment of Eef Schimmelpennink to its Board of Directors. With nearly 25 years of experience in the biotechnology sector, he aims to enhance the company’s efforts in neuroregeneration. Schimmelpennink has held prominent roles, including CEO of Pfenex and LENZ Therapeutics. His leadership is expected to advance Pipeline's promising portfolio, which includes two clinical candidates, PIPE-307 and PIPE-505, targeting neurological conditions. This strategic addition to the board could bolster the company's growth trajectory in the biopharmaceutical industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
management
Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) reported its financial results for the quarter ending December 31, 2021. The company added six new immuno-oncology assets to its pipeline and is advancing its COVID-19 vaccine candidate, IBIO-202, toward clinical trials. Revenues were approximately $0.2 million, a 76% decrease from the previous year, while R&D and G&A expenses increased by 40% and 48%, respectively. The net loss for the quarter was approximately $11.9 million. iBio expects adequate cash to fund operations through September 30, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
Rhea-AI Summary

iBio, Inc. (NYSEA:IBIO) announced it will report fiscal 2022 second quarter financial results on February 14, 2022, after market close. A conference call will be held at 4:30 PM ET to discuss these results and future corporate updates. iBio specializes in next-generation biopharmaceuticals, utilizing its innovative FastPharming Manufacturing System® for sustainable, plant-based biologics. The company aims to advance treatments for cancers and other diseases through high-quality monoclonal antibodies and proteins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences earnings
-
Rhea-AI Summary

iBio Updates on IBIO-202 COVID-19 Vaccine Development

iBio, Inc. (IBIO) announced progress on its COVID-19 vaccine, IBIO-202, which targets the nucleocapsid protein. Following FDA feedback, the company will conduct IND-enabling challenge studies and aims to submit an IND application by year-end 2022. This second-generation vaccine seeks to overcome waning immunity associated with first-generation vaccines that focus on the spike protein. iBio's research indicates that the N protein could stimulate a more durable immune response against emerging variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
covid-19
Rhea-AI Summary

iBio, Inc. (NYSE: IBIO) announced its participation in the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The company will provide a pre-recorded presentation accessible to all registered attendees and on its website beginning January 10. iBio specializes in next-generation biopharmaceuticals through its FastPharming Manufacturing System, which integrates vertical farming and automated hydroponics to produce high-quality proteins. The firm is focused on developing biopharmaceuticals for cancer, fibrotic, and infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
none

FAQ

What is the current stock price of iBio (IBIO)?

The current stock price of iBio (IBIO) is $2.48 as of December 20, 2024.

What is the market cap of iBio (IBIO)?

The market cap of iBio (IBIO) is approximately 22.2M.

What does iBio, Inc. specialize in?

iBio specializes in plant-based protein expression technologies for developing vaccines, therapeutic proteins, and biopharmaceutical products.

What are the main segments iBio operates in?

iBio operates in two main segments: Biopharmaceuticals and Bioprocessing.

What services does iBio offer?

iBio offers comprehensive development and manufacturing services, from early product selection to regulatory approval and commercial product launch.

Who comprises iBio’s team?

iBio's team includes knowledgeable protein scientists, microbiologists, and experts in manufacturing and regulatory affairs.

What are the key areas iBio's products target?

iBio's products target fibrotic diseases, cancers, and infectious diseases.

How does iBio's technology platform benefit clients?

iBio's technology platform provides significant time and cost advantages, enabling rapid development and seamless scale-up from preclinical to commercial production.

What recent achievements has iBio made?

iBio has made advancements in biotherapeutics and diagnostic products, showcasing its innovative capabilities.

What is iBio CDMO?

iBio CDMO is the division of iBio that handles bioprocessing activities, offering manufacturing and regulatory support.

Does iBio collaborate with other organizations?

Yes, iBio maintains strategic partnerships to enhance its research and development efforts.

How can I contact iBio for investor or media relations?

You can contact Stephen Kilmer for investor relations at skilmer@ibioinc.com or Susan Thomas for media relations at susan.thomas@ibioinc.com.

iBio, Inc.

NYSE:IBIO

IBIO Rankings

IBIO Stock Data

22.23M
9.14M
0.14%
31.49%
2.52%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK